SecBot SecBot

XLO drug pipeline

Xilio Therapeutics, Inc. · 4 rated drugs
$7.70
−4.6% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
4
4 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 1/2
Time to marketXTX501 is in early clinical development (Phase 1/2). Initial Phase 1 data is expected in Q4 2027. If successful, a registrational trial would follow, meaning potential approval is likely several years away (late 2029 or later under an accelerated timeline).

XTX501 Updated Nov 11

What to watch

The next meaningful catalyst for XTX501 is the initial Phase 1 data readout in Q4 2027, more than a year away. In the near term, watch for a trial-in-progress poster at the SITC meeting in November 2026 and any early safety signals. Xilio's cash runway into Q1 2028 provides a long enough runway to reach that data, but the stock may trade on broader pipeline news and quarterly earnings in the interim. The competitive landscape, particularly Innovent/Takeda's more advanced IBI363 program, will be an important benchmark for XTX501's potential.

Bull case
  • XTX501's masking technology could provide a best-in-class safety profile vs. unmasked IL-2 therapies, potentially enabling higher dosing and better efficacy
  • Analyst consensus is bullish: 5 of 6 analysts rate Buy/Strong Buy, with a mean price target of $18 (111% upside from the $8.53 close as of Nov 10, 2026)
  • Xilio has a cash runway into Q1 2028 ($122.2M as of Q3 2026), providing financial stability through the initial XTX501 data readout
Bear case
  • XTX501 is very early-stage (Phase 1/2, first patient dosed Oct 2026); no efficacy or safety data has been reported yet, making it a high-risk investment
  • Initial Phase 1 data is not expected until Q4 2027, over a year away, leaving a long period with no binary catalysts
  • Competition is intense: Innovent/Takeda's IBI363/TAK-928 (same PD-1/IL-2 alpha-biased bispecific mechanism) is already in registrational studies and has presented clinical data at ASCO and ESMO 2026
● neutral
Impact
PhasePreclinical
Time to marketNot stated

XTX701 Updated Nov 14

What to watch

XTX701 is a preclinical masked T cell engager with no IND submission timeline publicly disclosed. Investors should watch for Xilio's next corporate update or scientific conference presentation for any advancement of this program into IND-enabling studies. The nearer-term catalyst for Xilio is the Phase 1 data readout for XTX501 expected in Q4 2027, which carries more weight for the stock. XTX701-specific preclinical data could emerge at a future conference but no venue has been announced.

Bull case
  • XTX701 is a wholly-owned, novel masked T cell engager targeting two validated prostate cancer antigens (PSMA and STEAP1) simultaneously, designed to improve the therapeutic index over conventional T cell engagers by activating only in the tumor microenvironment.
  • Xilio's T cell engager platform (ATACR/SEECR formats) is backed by an AbbVie collaboration with $52M upfront and up to $2.1B in biobucks, providing external validation of the technology.
  • The company reported that development involved screening more than 1,800 molecules to optimize geometry and targeting arms, suggesting a thorough preclinical optimization process.
Bear case
  • XTX701 remains preclinical with no IND filing or clinical trial registration on ClinicalTrials.gov as of November 2026, meaning it is likely years away from any value-inflecting clinical data.
  • Prostate cancer T cell engagers are a competitive space with multiple approved and investigational agents from larger companies (Amgen's BLINCYTO platform, Janssen's talquetamab, etc.), and Xilio's masked approach has not yet been clinically validated for this target combination.
  • Xilio is a micro-cap (~$60M market cap) with an exposed balance sheet; though cash of $122.2M provides runway into Q1 2028, the company has multiple pipeline programs competing for capital, and earlier-stage programs like XTX701 could be deprioritized.
● neutral
Impact
PhasePhase 2
Time to marketEfarindodekin alfa is in Phase 2 testing. Assuming successful trials and regulatory review, potential approval would likely be several years away (2029 or later), though the Gilead partnership could accelerate development if Gilead exercises its option.

efarindodekin alfa Updated Nov 11

What to watch

Efarindodekin alfa (XTX301) is in an ongoing Phase 2 monotherapy trial with no announced data readout date. The next major pipeline catalyst for Xilio is the XTX501 Phase 1 data expected in Q4 2027. Investors should watch for any update on XTX301 Phase 2 enrollment progress or potential Gilead exercise of its option to take over development, which would trigger a $75 million transition fee.

Bull case
  • Phase 1 data showed efarindodekin alfa was generally well-tolerated at doses over 100-fold greater than the maximum tolerated dose of recombinant human IL-12, with primarily Grade 1-2 treatment-related adverse events, suggesting the masking technology may solve IL-12's historical toxicity problem.
  • Phase 1 data demonstrated promising monotherapy anti-tumor activity in advanced solid tumors, a difficult-to-treat patient population.
  • The program is backed by Gilead Sciences through an exclusive license agreement, with a $17.5M milestone already achieved and a potential $75M transition fee if Gilead exercises its option to take over development.
Bear case
  • Efarindodekin alfa is still in early-to-mid-stage clinical development (Phase 2) with no approved products, meaning a high risk of clinical failure. IL-12 has historically been a difficult target with significant toxicity challenges.
  • No specific data readout date has been announced for the Phase 2 trial, creating an uncertain timeline for the next catalyst.
  • Xilio had only $5.9M in Q3 2026 revenue and a net loss, with cash runway extending only into Q1 2027, creating potential financing risk if milestones are delayed.
● neutral
Impact
PhasePreclinical / IND-enabling
Time to marketIND filing planned for Q4 2027; if approved, earliest commercialization would be many years away, contingent on successful Phase 1, Phase 2, and Phase 3 trials.

XTX602 Updated Nov 14

What to watch

The next catalyst for XTX602 is an IND filing planned for Q4 2027, which is roughly 12 months away. The nearer-term drivers for XLO stock are the Gilead option decision on XTX301 (H1 2027) and initial Phase 1 data for lead asset XTX501 (Q4 2027). Until XTX602 enters the clinic, investors will value XLO primarily on XTX501 progress and partnership outcomes.

Bull case
  • Xilio's cash position of $122.2M provides runway into Q1 2028, giving XTX602 ample time to reach the clinic without near-term financing pressure.
  • The company's masked immuno-oncology platform has been validated by a Gilead partnership for XTX301 (tumor-activated IL-12), lending credibility to platform derivatives like XTX602.
  • Analyst consensus is bullish (5 Buy/Strong Buy, 1 Hold, 0 Sell) with a mean price target of $18, implying 122.9% upside from the $8.075 close.
Bear case
  • XTX602 is preclinical/IND-enabling, with an IND filing not expected until Q4 2027; it may never reach the clinic or fail in development.
  • Xilio has no approved products and its only revenue is from collaboration agreements ($10.0M in Q3 2026, down 47.6% YoY). The stock has a tiny market cap (~$58M) and is a single-miss away from distress.
  • The company executed a 1-for-14 reverse stock split in March 2026, signaling prior share-price distress, and further dilution from Series C warrant exercises (up to $36.2M) looms.

Other drugs in filings and trials

no drug report yet

Clinical trials

2 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
vilastobart (XTX101)Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid TumorsPhase 2Completed125May 18, 2026
XTX202XTX202 in Patients With Advanced Solid TumorsPhase 2Completed · results95Mar 22, 2025